previous SHCS study measuring immune response with any available YF plaque reduction neutralization titer (PRNT) measurement between 1 year and 10 years postvaccination (p.v.) in 70 vaccinees after the last of 1 or more documented YFVs pointed toward an impaired immune response over time (seropositivity rate of 77%) [15] .
We used stored SHCS samples to measure the short-and long-term immune responses at defined times after first documented YFV in HIV-infected patients to evaluate whether and when a booster vaccination should be recommended. We also investigated possible predictors for an adequate immune response to YFV in HIV-infected persons, and evaluated the safety of YFV.
METHODS

Patients and Data Collection
The prospective SHCS (www.shcs.ch) is a systematic longitudinal cohort based at 7 centers, and affiliated hospitals and physicians in Switzerland. SHCS collects clinical and laboratory data from patients upon enrollment and follow-up visits every 6 months. Plasma samples are obtained and stored at -75°C [14] . A questionnaire is also used to inquire, among other things, about travel to tropical countries and, since 2009, about receipt of YFV.
Six SHCS centers participated in this study and recorded information on YFV from participants with at least 1 SHCS follow-up visit between 1 January 1989 and 31 December 2013. We also included SHCS participants from our previous YFV study [15] that was based on evaluating all SHCS patients of 4 centers with a history of travel to the tropics and who could have been missed by the SHCS variable on YFV only introduced in 2009.
Patients were asked to provide all available vaccination cards to verify YFV dates, and for this we also checked local vaccination center databases, documents, and medical charts. All local ethical committees have approved the SHCS, and all participants gave written informed consent before enrollment.
Participants >18 years of age with a first documented dose of YFV following HIV diagnosis were included if verification of the date of YFV was possible by either (1) a vaccination card or vaccination center documentation (252/276 total vaccinations [91%]); (2) information in patient medical records as reviewed by 2 individuals (13 vaccinations [5%]); or (3) information from our previous study [15] if precise information on the vaccine type (Stamaril or another) was known (11 vaccinations [4%] ). Vaccinees in our previous study [15] who did not fulfill these criteria were not included. All YFV dates were included and classified as first, second, or third vaccination for each participant. Those who had been vaccinated <1 year before documented HIV diagnosis were classified as being HIV infected at vaccination unless HIV seroconversion within this year was documented.
As possible predictors of protective immune response at first documented YFV (baseline) and p.v., we extracted the following from the SHCS database: age, sex, origin in a YF-endemic country, Centers for Disease Control and Prevention (CDC) HIV classification, hepatitis B or C coinfection, smoking habits (±180 days around vaccination), combination antiretroviral therapy (cART), CD4 cell count nadir before first vaccination, the closest CD4 cell count value around the time of YFV (±365 days), and HIV RNA (<1 year before YFV). HIV RNA <400 copies/ mL was defined as suppressed HIV RNA load. The SHCS database was checked for hospitalizations and death within 90 days following YFV.
Evaluation of Immunogenicity
SHCS plasma samples frozen and stored before and after YFV were retrieved from all centers and sent on dry ice to the Robert Koch Institute, Berlin, Germany. Samples were analyzed at 4 intervals: (1) before YFV from any time prior to vaccination; (2) 1 year, which covered the interval from 30 to 365 days p.v. for the short-term immune response; (3) 5 years, which included samples assayed between 4 and 6 years p.v., and (4) 10 years, for sample assays between 9.5 and 11 years p.v.
At the Robert Koch Institute, all plasma samples were analyzed twice and in 2-fold dilutions (range, 1:5 to 1:>320) using a YF plaque reduction neutralization test [16] . The plaques caused by lysis of infected cells were counted and the 90% PRNT was calculated. Serum from a healthy vaccinee with known titer was included as positive control in all assays to assure interassay reproducibility. PRNTs of 1:≥10 are defined as reactive or detectable, and those of 1:<10 as nonreactive or undetectable PRNT [17] . PRNT of 1:≥10 is generally believed to be a serological surrogate for protection against wild-type YF virus [18] . Decreasing PRNT was modeled as log 10 of the reciprocal neutralization titer over time.
Statistical Analysis
We report the proportion and 95% confidence intervals (CIs) of blood samples categorized as reactive. Univariable and multivariable Poisson regression models were used to analyze characteristics associated with reactive PRNT as a binary outcome within the first year and after 5 and 10 years p.v. [19] . Linear regression was used for univariable and multivariable analysis of parameters associated with the value of PRNT. The multivariable regression models included CD4 cell count nadir before YFV, HIV RNA <400 copies/mL as a binary variable, and CD4 cell count at time of YFV, age, sex, chronic hepatitis B/C, origin in a YF-endemic country, and having nonreactive PRNT before first YFV. Smoking was not included in the multivariable analysis, as information was often missing and smoking habits can change rapidly. Square-root CD4 cell count values and log 10 of the reciprocal neutralization titer were implemented in the regression model. Analyses were conducted using Stata software version 13 (StataCorp, College Station, Texas). (20) 3 (8) 200-349 25 (11) 10 (10) 6 (7) 9 (21) 2 (20) 20 (11) 1 (9) 10 (10) 1 (10) 5 (13) 350-499 60 (27) 32 (32) 18 (22) 10 (23) 2 (20) 48 (25) 3 (27) 25 (25) 3 (30) 
RESULTS
Study Population
We identified 247 participants with at least 1 documented YFV after HIV diagnosis; 27 participants had received 2 doses, and 2 participants had received 3 YFV doses ( Figure 1 ). More than half of the participants were from sub-Saharan Africa. Baseline characteristics and laboratory findings are listed in Table 1 . At baseline, the majority of the patients were taking cART (82%), had suppressed HIV RNA (83%), and their median CD4 cell count was 536 cells/μL. Eleven patients had been vaccinated at a CD4 cell count <200 cells/μL (range, 11-193 cells/μL).
Short-term and Long-term Immune Responses
Results of the immune response are summarized in Table 2 . Plasma before vaccination was available for 182 of the 247 patients (74%), and for 201 patients at 1 year (81%), 122 patients at 5 years (49%), and 63 patients at 10 years (26%). The proportions of patients with reactive PRNT at these intervals are shown in Figure 2A . A longitudinal PRNT determination at all times was possible for 33 participants (Supplementary Figure 1) . The proportions with reactive PRNT in this group were 30% (95% CI, 16%-49%) prevaccination, 91% (76%-98%) at 1 year p.v., 94% (80%-99%) at 5 years p.v., and 82% (65%-93%) at 10 years p.v. and were similar to the whole population. The magnitude of PRNT also dropped over time ( Figure 3A and 3B). Forty-six percent of the vaccinees had reactive PRNTs at baseline. This was more likely for patients originating from a YF-endemic country (P = .02). Figure 2B shows the vaccine response among the 99 vaccinees with nonreactive PRNT before the first YFV. The vaccine response among those with HIV RNA suppressed at baseline was >95% at all times and is shown in Figure 2C , and for patients with suppressed HIV RNA and nonreactive PRNT at baseline in Figure 2D .
In patients with unsuppressed HIV RNA at baseline, reactive PRNT was found in 83% (95% CI, 66%-93%; 29/35 patients) within 1 year p.v., 83% (63%-95%; 20/24 patients) at 5 years p.v., and 43% (18%-71%; 6/14 patients) at 10 years p.v. The proportions were even lower in patients with nonreactive PRNT and unsuppressed HIV RNA at baseline. The 16 patients with nonreactive PRNT at 10-year follow-up had been vaccinated between 1986 and 2003, and in no patients with available viral load data (n = 8) was HIV RNA suppressed at baseline.
Association of Baseline Parameters With Immune Response
Suppressed HIV RNA at baseline was associated with reactive PRNT at 1 year, 5 years, and 10 years, with the strongest association at 10 years (relative proportion = 2.1 [95% CI, 1.2-3.6]). Vaccinees with nonreactive PRNT at baseline had a lower probability, and those originating from a YF-endemic country a higher probability, of reactive PRNT within 1 year after vaccination but not thereafter (Table 3) . In a multivariable subanalysis in 95 patients who had nonreactive PRNT at baseline, no significant association was seen between patients originating from a YF-endemic country and reactive PRNT at 1 year p.v. (P = .08., data not shown). Suppressed HIV RNA at baseline was also the strongest predictor of the magnitude of immune response to YFV at 1, 5, and 10 years p.v. (Supplementary Table 1) .
A >3-fold PRNT increase to >1:90 was observed in 4 patients from 1 year to 5 years p.v. and in 4 patients from 5 to 10 years p.v. For these vaccinees, we could not identify a booster YFV.
Safety
Two patients were hospitalized 55 and 90 days after vaccination but did not fulfill the case definition of suspected visceral or neurologic disease [8, 20] . Sixty of 247 vaccinees (24%) had received YFV before SHCS registration, including 9 of 11 patients who received YFV with CD4 cell count <200 cells/μL at baseline. These 11 patients are characterized in Supplementary Table 2 , and a reactive PRNT was seen for 5 of 7 patients at 1 year p.v., for 2 of 8 patients at 5 years p.v., and for 3 of 5 patients at 10 years p.v.
DISCUSSION
Persons infected with HIV demonstrated good short-term immune response to YFV of 95%, which decreased to 75% 10 years p.v. The long-term immune response of patients with HIV RNA suppressed at vaccination remained unimpaired for up to 10 years.
Participants' short-term immune response within 1 year of vaccination was slightly impaired compared with the reported seroconversion rate of up to 99% within 30 days p.v. in HIVuninfected persons [1] , but higher than previously reported in our cohort [15] . This is likely due to a higher proportion of patients on successful cART at baseline who showed a response of 99%-100%, but could also be partly due to a high proportion of patients with reactive PRNT before first documented YFV. A French study also found a PRNT 1:≥10 in 44 of 45 (98%) HIVinfected vaccinees [10] and, in a YF-endemic country, 76 of 83 HIV-infected patients (92%) responded to YFV [12] . Other small series have shown similar results [9, 11, 21] , with the exception of 1 study with seroprotection of only 17% in HIVinfected children in Côte d'Ivoire, where problems with vaccine storage and/or administration were suspected [22] .
The longer-term immune response to YFV decreased in our whole population from 95% at 1 year p.v. to 86% at 5 years p.v. and 75% at 10 years p.v., while the respective proportions with reactive PRNT in patients with suppressed HIV RNA remained high. Quantitative antibody titers were also higher at all times in patients with plasma HIV RNA suppressed at baseline, although titers decreased over time ( Figure 3A) . A decrease of the proportion of reactive PRNTs similar to that observed in our total population was reported in immunocompetent vaccinees in a Brazilian study, with a gradual decrease of PRNT from 94% at 1-4 years to 83% at 5-9 years and 76% at 10-11 years [5] . In our patients with suppressed HIV replication, the long-term results up to 10 years are similar to those of a general population reported in a recent systematic review that estimated a seropositivity rate of 92% (95% CI, 85%-96%) at ≥10 years p.v. [23] .
Data on the long-term immunity to primary YFV among HIV-infected persons are scarce. In a recent small series, 7 of 13 and then 4 of 8 patients had protective titers after a follow-up of 5 and 10 years, respectively [24] . Pacanowski et al observed seropositivity in 66 of 72 French HIV-infected travelers (92%) with PRNT determination >10 years p.v. [10] -a result closer to our observation in patients with suppressed viremia at baseline. However, 57 of the 72 French patients had been vaccinated before HIV infection was diagnosed, and those with booster vaccinations appear to have been included. Both could have positively influenced the immune response. The decrease we observed in quantitative PRNT over time was similar to that reported by Pacanowski et al and a small Brazilian study [10, 24] .
Although we carefully tried to retrieve all previous YFV dates, >40% of patients were found to have reactive PRNT before first documented YFV, which indicates either prior YFV or past exposure to wild-type YF virus or, less likely, other flaviviruses. It is not possible to differentiate whether PRNT 1:≥10 is due to wildtype YF virus or due to 17D vaccine. A subanalysis of vaccinees with nonreactive PRNT at baseline showed a PRNT seropositivity rate after 10 years similar to that of patients with reactive PRNT at baseline. Furthermore, originating from YF-endemic countries or having reactive PRNT before first documented YFV was associated with a better immune response only in the short term, but not the longer term. Thus, even though we cannot exclude prior YFV in all participants, the immune response of our whole population seems to be representative.
Suppressed HIV RNA at baseline was the main predictor in our study for developing and maintaining protective immune response. Successful cART reduces immune activation, improves T-helper response, has been shown to ameliorate immune responses to other vaccines [25] [26] [27] [28] , and also reduces the incidence of opportunistic infections independent of the current CD4 cell count [29] . More than 90% of Swiss HIV-infected persons on cART remain suppressed over time [30] . In fact, all our patients with HIV RNA suppressed at baseline were virologically controlled at the 10-year follow-up determination of vaccine response (data not shown). Thus, HIV-infected patients mount a long-standing protective immune response to YFV up to at least 10 years if they are vaccinated while remaining on successful cART. Whether this immunity after a single primary dose of YFV is lifelong, as suggested by WHO for immunocompetent persons, still remains to be shown. However, even this WHO recommendation is controversial, in particular concerning travelers residing in non-YF-endemic countries [4] [5] [6] [7] . Therefore, until further data are available, a single booster after 10 years seems to be adequate to restimulate the vaccine response in the event of new travel to a YF-endemic region. If time allows, testing of YF PRNT before travel is also an option.
The effect of suppressed HIV RNA load on long-term YFV immunity seems to hold true irrespective of age, sex, hepatitis coinfection, or region of origin. Neither the CD4 cell count nor CD4 cell count nadir appears to have a major influence as long as it is in range observed in our population. In a Brazilian cross-sectional analysis, the CD4/CD8 ratio, but not absolute CD4 cell count at the time of serological testing, was positively associated with immune response to YF vaccine [24] . All the participants had undetectable plasma HIV RNA at the time of serological analysis. The CD4/CD8 ratio is a marker both of Stored samples allowed longitudinal evaluation of serologic response. We are not aware of any other large study in HIV-infected patients analyzing individual longitudinal data after YFV. We observed a few patients in whom the titer increased during follow-up even though a booster YFV was ruled out with certainty. This may be due to ongoing immune reconstitution on cART or a cross-reaction after exposure to or vaccination against other flaviviruses or unspecific broad B-cell activation as seen after mononucleosis-like infections. Reactive PRNT before YFV was not statistically associated with higher titers 5 and 10 years p.v. (Supplementary Table 1) . No deaths or viscerotropic or neurological disease occurred following YFV in 187 patients who were vaccinated during prospective follow-up in SHCS. However, the number of vaccinees studied was not large enough to reliably assess small risks. One limitation of this research is that the results of a retrospective study within a prospective cohort did not allow systematic determination of PRNT for all patients at precisely defined postvaccination intervals. Nevertheless, due to prospectively stored SHCS plasma samples, this study provides a valuable longitudinal, individual follow-up of PRNTs. The majority of patients with PRNT determinations 5 or 10 years p.v. also had had a PRNT determination within 1 year p.v., with a proportion of protective PRNTs in the follow-up similar to the whole study population.
CONCLUSIONS
In this large cohort study, HIV-infected patients' long-term immune response up to 10 years to YFV is primarily dependent on the control of HIV replication at the time of vaccination. Vaccinees on successful cART had high levels of reactive PRNT, and protective titers were maintained up to 10 years. Our results point toward acceptable safety of YFV in HIV-infected individuals on cART.
Until further data on long-term immunity are available, we recommend that HIV-infected patients should be vaccinated against YF once their HIV RNA is suppressed and receive a YFV booster after 10 years if they stay on uninterrupted successful cART to restimulate the vaccine response. However, HIV-infected persons who were vaccinated with replicating HIV should either have their PRNT measured or receive a booster YFV while on successful cART, irrespective of time elapsed since primary YFV.
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